Sam Lanyon
Chairman at LUMOS DIAGNOSTICS HOLDINGS LIMITED
Sam Lanyon active positions
Companies | Position | Start | End |
---|---|---|---|
LUMOS DIAGNOSTICS HOLDINGS LIMITED | Chairman | 2018-12-31 | - |
Chief Executive Officer | 2022-04-10 | 2022-06-20 | |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | Director/Board Member | - | - |
Lumos Diagnostics
Lumos Diagnostics Medical SpecialtiesHealth Technology Lumos Diagnostics develops and provides diagnostic solutions. It offers assay development, reader development, and point-of-care diagnostic solutions. The company is headquartered in Carlsbad, CA. | Chairman | - | - |
Planet Innovation Pty Ltd.
Planet Innovation Pty Ltd. Medical SpecialtiesHealth Technology Planet Innovation Pty Ltd. is a healthtech innovation and Australian commercialization company that specializes in product development and manufacturing. The private company is based in Box Hill, AU. and has subsidiaries in the United States. It was founded in 2009 by Eduardo Vom, Sam Lanyon, Stuart Elliott, and Troy O'Callaghan, with Stuart Elliott serving as the CEO since its inception. | Director/Board Member | 2008-12-31 | - |
Founder | 2008-12-31 | - | |
Chief Executive Officer | 2008-12-31 | - |
Career history of Sam Lanyon
Former positions of Sam Lanyon
Companies | Position | Start | End |
---|---|---|---|
Zen Ecosystems | Director/Board Member | - | - |
Waterwerx Pty Ltd. | Director/Board Member | - | - |
Training of Sam Lanyon
University of Melbourne | Undergraduate Degree |
Statistics
International
Australia | 5 |
United States | 4 |
Operational
Director/Board Member | 4 |
Chairman | 2 |
Chief Executive Officer | 2 |
Sectoral
Health Technology | 5 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
LUMOS DIAGNOSTICS HOLDINGS LIMITED | Health Technology |
Private companies | 5 |
---|---|
Waterwerx Pty Ltd. | |
Planet Innovation Pty Ltd.
Planet Innovation Pty Ltd. Medical SpecialtiesHealth Technology Planet Innovation Pty Ltd. is a healthtech innovation and Australian commercialization company that specializes in product development and manufacturing. The private company is based in Box Hill, AU. and has subsidiaries in the United States. It was founded in 2009 by Eduardo Vom, Sam Lanyon, Stuart Elliott, and Troy O'Callaghan, with Stuart Elliott serving as the CEO since its inception. | Health Technology |
Lumos Diagnostics
Lumos Diagnostics Medical SpecialtiesHealth Technology Lumos Diagnostics develops and provides diagnostic solutions. It offers assay development, reader development, and point-of-care diagnostic solutions. The company is headquartered in Carlsbad, CA. | Health Technology |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | Health Technology |
Zen Ecosystems |
- Stock Market
- Insiders
- Sam Lanyon
- Experience